Saturday, October 31, 2026

MicroStrategy Stock Impressive Jump On Tuesday, Outperforms Market

ViaNews Editorial Team

October 24, 2023

MicroStrategy Stock  Impressive Jump On Tuesday, Outperforms Market

(VIANEWS) - The NASDAQ ended the session with MicroStrategy (MSTR) jumping 12.31% to $423.96 on Tuesday while NASDAQ jumped 0.93% to $13,139.88.

MicroStrategy's last close was $377.49, 20.54% below its 52-week high of $475.09.

About MicroStrategy

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $9.36.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 45.29. Meaning, the purchaser of the share is investing $45.29 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 65.4%.

Volatility

MicroStrategy's last week, last month's, and last quarter's current intraday variation average was 1.26%, 0.40%, and 2.45%.

MicroStrategy's highest amplitude of average volatility was 2.52% (last week), 2.36% (last month), and 2.45% (last quarter).

Moving Average

MicroStrategy's worth is way higher than its 50-day moving average of $341.14 and way above its 200-day moving average of $311.49.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 4.9%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 131% and 102.1%, respectively.

More news about MicroStrategy (MSTR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com